SAN

97.55

-3.11%↓

EI

247

-3.36%↓

SHL.DE

46.65

-3.18%↓

ARGX

529.2

-2.72%↓

FRE

39.16

-0.74%↓

SAN

97.55

-3.11%↓

EI

247

-3.36%↓

SHL.DE

46.65

-3.18%↓

ARGX

529.2

-2.72%↓

FRE

39.16

-0.74%↓

SAN

97.55

-3.11%↓

EI

247

-3.36%↓

SHL.DE

46.65

-3.18%↓

ARGX

529.2

-2.72%↓

FRE

39.16

-0.74%↓

SAN

97.55

-3.11%↓

EI

247

-3.36%↓

SHL.DE

46.65

-3.18%↓

ARGX

529.2

-2.72%↓

FRE

39.16

-0.74%↓

SAN

97.55

-3.11%↓

EI

247

-3.36%↓

SHL.DE

46.65

-3.18%↓

ARGX

529.2

-2.72%↓

FRE

39.16

-0.74%↓

Search

BioMerieux

Closed

SectorHealthcare

119 1.97

Overview

Share price change

24h

Current

Min

115.8

Max

119.9

Key metrics

By Trading Economics

Income

215M

Sales

-1.1B

785M

P/E

Sector Avg

31.374

63.778

Dividend yield

0.77

Profit margin

11.32

Employees

14,147

EBITDA

-247M

161M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+15.58% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.77%

2.39%

Market Stats

By TradingEconomics

Market Cap

14B

Previous open

117.03

Previous close

119

News Sentiment

By Acuity

19%

81%

36 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

BioMerieux Chart

Past performance is not a reliable indicator of future results.

Related News

3 Apr 2025, 23:04 UTC

Top News

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 Apr 2025, 22:40 UTC

Major Market Movers

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 Apr 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 Apr 2025, 18:51 UTC

Acquisitions, Mergers, Takeovers

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 Apr 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 Apr 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 Apr 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 Apr 2025, 22:21 UTC

Acquisitions, Mergers, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 Apr 2025, 21:43 UTC

Top News
Earnings

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 Apr 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 Apr 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 Apr 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 Apr 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 Apr 2025, 20:34 UTC

Top News

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 Apr 2025, 20:23 UTC

Top News

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 Apr 2025, 20:15 UTC

Acquisitions, Mergers, Takeovers

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 Apr 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 Apr 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 Apr 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 Apr 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 Apr 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 Apr 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3 Apr 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 Apr 2025, 18:38 UTC

Top News

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 Apr 2025, 18:30 UTC

Top News

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 Apr 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 Apr 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 Apr 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 Apr 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 Apr 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

BioMerieux Forecast

Price Target

By TipRanks

15.58% upside

12 Months Forecast

Average 133.5 EUR  15.58%

High 140 EUR

Low 129 EUR

Based on 6 Wall Street analysts offering 12 month price targets forBioMerieux - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

115.8 / 117.5Support & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

36 / 386 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.